Laparoscopic Tubal Disconnection Versus Laparoscopic Salpingectomy in Infertile Patients

Sponsor
Ain Shams Maternity Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06015698
Collaborator
(none)
150
2
12

Study Details

Study Description

Brief Summary

Tubal factor infertility is known to be one of the most common indications for IVF treatment. Patients with hydrosalpinges have been identified to have poor pregnancy outcomes such as lower implantation and pregnancy rates & higher rates of spontaneous abortion and ectopic pregnancies. Surgical intervention can be recommended for patients with hydrosalpinx prior to IVF/ICSI.

This study will be done at Ain Shams University Maternity Hospital, to compare laparoscopic salpingectomy & laparoscopic tubal disconnection as two surgical modalities of treatment of unilateral or bilateral hydrosalpinges in women older than 30 years and scheduled for IVF/ICSI, regarding implantation rates, clinical pregnancy rates, ongoing pregnancy rates, ectopic pregnancy rates, and operative complications.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Laparoscopic tubal disconnection
  • Procedure: Laparoscopic salpingectomy
N/A

Detailed Description

It is estimated that tubal factors account for 14% of the causes of subfertility in women. The prevalence of hydrosalpinx among tubal diseases is as high as 30% of couples presenting with infertility from tubal factors.

Hydrosalpinx is the dilation of the fallopian tube in the presence of distal tubal occlusion, which may result from several causes. The leading cause of distal tubal occlusion is pelvic inflammatory disease (PID), usually resulting from a prior sexually transmitted disease, such as Chlamydia trachomatis or Neisseria gonorrhoeae. Tubal tuberculosis is an uncommon cause of hydrosalpinx, though re-emerging in developed countries. Other etiologies include endometriosis, appendicitis, and abdominopelvic surgery.

Depending on several patient factors, tubal microsurgery, or more commonly IVF with its improving success rates, are the recommended treatment options for tubal factor infertility.

In addition to its essential role in infertility, hydrosalpinx has an adverse effect on the outcome of in vitro fertilization (IVF) Hydrosalpinx can decrease the clinical pregnancy rate of IVF-ET, and increase the incidence of abortion and ectopic pregnancy.

The presence of hydrosalpinx has a negative effect on IVF/ET because of the suspected embryotoxicity of the hydrosalpingeal fluid due to a combination of mechanical and chemical factors thought to disrupt the endometrial environment.

Surgical treatment should be considered for all women with hydrosalpinges prior to IVF treatment (Johnson et al .,2004 )

Removing (salpingectomy) or occluding blocked or diseased fallopian tubes before IVF can increase pregnancy and live birth rates for women on the IVF program.

A network meta-analysis showed that Proximal tubal occlusion, salpingectomy, and aspiration for treatment of hydrosalpinx scored consistently better than did no intervention for the outcome of IVF/ET. Tubal occlusion and salpingectomy also improve ongoing pregnancy rates. Proximal tubal occlusion ranks highest for most of the outcomes assessed, whereas no intervention scores consistently as the least effective strategy for all outcomes

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Laparoscopic Tubal Disconnection Versus Laparoscopic Salpingectomy in Infertile Patients Scheduled for IVF/ICSI. Randomized Controlled Trial
Anticipated Study Start Date :
Aug 30, 2023
Anticipated Primary Completion Date :
Aug 30, 2024
Anticipated Study Completion Date :
Aug 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Tubal disconnection

The tube is grasped in the isthmic portion of the tube at least 2cm from the cornua. Bipolar coagulation will provide a more localized area of tubal burn so requiring at least 3cm of the tube to be coagulated The electrosurgical generator should set to deliver a power of 25W in nonmodulated mode to desiccate tissue sufficiently The tube should be coagulated with 2 to 3 contiguous burns to provide an area of about 3cm of coagulation. Th endpoint of coagulation is cessation of the current flow Then, the tube is severed in the middle of the burn area with laparoscopic scissors Ensure adequate hemostasis

Procedure: Laparoscopic tubal disconnection
The tube is grasped in the isthmic portion of the tube at least 2cm from the cornua. Bipolar coagulation will provide a more localized area of tubal burn so requiring at least 3cm of the tube to be coagulated The electrosurgical generator should set to deliver a power of 25W in nonmodulated mode to desiccate tissue sufficiently The tube should be coagulated with 2 to 3 contiguous burns to provide an area of about 3cm of coagulation. Th endpoint of coagulation is cessation of the current flow Then, the tube is severed in the middle of the burn area with laparoscopic scissors Ensure adequate hemostasis

Active Comparator: Salpingectomy

The tube will be removed from its anatomical attachements by progressive bipolar coagulation Progressive coagulation and cutting of the mesosalpinx begins at the proximal isthmus of the tube and progresses to the fimbriated end using bipolar coagulation and laparoscopic scissors Removal of the tube through one of the ancillary ports using artery forceps Ensure adequate hemostasis

Procedure: Laparoscopic salpingectomy
The tube will be removed from its anatomical attachements by progressive bipolar coagulation Progressive coagulation and cutting of the mesosalpinx begins at the proximal isthmus of the tube and progresses to the fimbriated end using bipolar coagulation and laparoscopic scissors Removal of the tube through one of the ancillary ports using artery forceps Ensure adequate hemostasis

Outcome Measures

Primary Outcome Measures

  1. Ongoing pregnancy rate [From 10 + 0 weeks of gestation]

    Pregnancy with detectable heart beat 10weeks gestation or beyond

Secondary Outcome Measures

  1. Operative time [in minutes starting from laparoscopic entry into the peritoneal cavity till removal of the primary trocar from the cavity]

    in minutes starting from laparoscopic entry into the peritoneal cavity till removal of the primary trocar from the cavity

  2. Intraoperative complications [During the procedure]

    Bowel injury - Vascular injury

  3. Postoperative complications [First 48 hours after the procedure]

    ileus - surgical emphysema

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 40 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Infertile ( primary or secondary ).

  2. Age > 30 years .

  3. HSG with unilateral or bilateral hydrosaalpinx , confirmed laparoscopically.

  4. Scheduled for IVF/ICSI

Exclusion Criteria:
  1. Contraindications for laparoscopy
  • Cardiac disease.

  • BMI > 40 kg/m²

  • Previous midline incision .

  • Past history of TB peritonitis .

  1. Proximal tubal block by HCG .

  2. Frozen pelvis proved by previous laparoscopy or laparotomy .

  3. Allergy to contrast media of HSG .

  4. Premature ovarian failure (Serum FSH >40 mIU/ml )

  5. Prescence of Male factor contributing to the infertility proved by abnormal semen analysis

  6. Prescence of Ovarian factor contributing to the infertility proved by the prescence of features suggesting anovulation

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Ain Shams Maternity Hospital

Investigators

  • Study Director: Hamdy B Alqenawy, M.D.,, Ain Shams university - Faculty of Medicine
  • Principal Investigator: Ahmed G Abd Elrahim, M.D.,, Ain Shams university - Faculty of Medicine
  • Principal Investigator: Alaa S Elsewafy, M.D.,, Ain Shams university - Faculty of Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ahmed Mohammed Elmaraghy, Lecturer in Obstetrics and Gynecology, Ain Shams Maternity Hospital
ClinicalTrials.gov Identifier:
NCT06015698
Other Study ID Numbers:
  • 10
First Posted:
Aug 29, 2023
Last Update Posted:
Aug 29, 2023
Last Verified:
Aug 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 29, 2023